UNITED STATES- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its chart ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - CEO James Gruber - CFO Conference Call Participants James Kennedy - Marathon Micro Partners Operator Good afternoon and welcome to the Eton Pharmaceuticals' Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen only mode. Following the formal remarks, we will open the call out for your ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______ TO ______ Commission File Number 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 37-1858472 (State or o ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants David Krempa - Senior Vice President, Business Development & Investor Relations Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Operator Good afternoon and welcome to the Eton Pharmaceuticals' Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen only mode. Following the formal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 | --- | --- | --- | |------------------------------------------------------ ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants David Krempa - Senior Vice President of Business Development & Investor Relations Sean Brynjelsen - President & Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good afternoon and welcome to the Eton Pharmaceuticals Second Quarter '22 Financial Results Conference Call. [Operator Instructions] P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Reimagining Molecules to Advance Medicine Corporate Presentation – April 2022 | | | | | | | | | | | | | Safe Harbor SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document contains forward-looking statements concerning Eton Pharmaceuticals, Inc. ("Eton", the "Company," ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants David Krempa – Senior Vice President-Business Development and Investor Relations Sean Brynjelsen – Chief Executive Officer James Gruber – Chief Financial Officer Conference Call Participants Mitchell Kapoor – H. C. Wainwright Justin Walsh – B. Riley Operator Good afternoon. And welcome to the Eton Pharmaceuticals’ First Quarter 2022 Financial Results Conference Call. At this time, all parti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charte ...